Teva Launches First-Ever CREATES Act Suit
Seeks Help With Fabry Disease Generic Development
Executive Summary
Amicus should to be forced to sell samples of Galafold (migalastat) for bioequivalence and other testing, Teva argues in what appears to be the initial case brought under the 2019 law intended to smooth the development of ANDAs.
You may also be interested in...
Amicus' Acquiescence To Teva Reflects Power Of CREATES Act
Teva has dismissed its suit against Amicus Therapeutics after the latter agreed to provide requested quantities of its Fabry disease treatment Galafold. The quick resolution of the complaint illustrates the success of the CREATES Act in halting the drug supply dispute but leaves some unanswered questions.
ANDA Approval Decline Continues, But Why?
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
AAM Calls For A Balance Instead Of Banning Pay-For-Delay
US President Joe Biden has signed an executive order asking the FTC to ban so-called “pay-for-delay” reverse-payment settlements. According to the order, this could help curb high prices that are in part the result of lack of competition among drug manufacturers. However, talking exclusively to Generics Bulletin, AAM senior vice president Jeff Francer insists on a balance, explaining that such settlements result in earlier access to biosimilars and generics.